Legend Biotech's shares surged over 40% following the announcement of promising early data on its in vivo CAR-T therapy for Non-Hodgkin's lymphoma, making it a standout performer amid a broader decline in biotech stocks. The article also highlights new guidance for gene therapy developers and Eli Lilly's recent licensing deal for kidney drugs.
Legend Biotech's recent 40% surge in stock prices, driven by promising early data on its in vivo CAR-T therapy for Non-Hodgkin’s lymphoma, signals a significant advancement in the biotech sector, particularly in personalized cancer treatment. This development highlights the potential growth and investment opportunities in companies focusing on innovative gene therapies, suggesting a strategic area for investment and partnership for stakeholders in healthtech and biotech industries.